MicroRNAS in endometrial cancer: recent advances and potential clinical applications

Authors

  • Megumi Yanokura Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan
  • Kouji Banno Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan
  • Miho Iida Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan
  • Haruko Irie Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan
  • Kiyoko Umene Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan
  • Kenta Masuda Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan
  • Yusuke Kobayashi Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan
  • Eiichiro Tominaga Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan
  • Daisuke Aoki Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan

DOI:

https://doi.org/10.17179/excli2014-590

Keywords:

microRNA, endometrial cancer, biomarker, OncomiR, tumor suppressor miR

Abstract

Endometrial cancer is a common malignant gynecological tumor, but there are few biomarkers that are useful for early and accurate diagnosis and few treatments other than surgery. However, use of microRNAs (miRNAs) that induces gene downregulation in cells may permit effective and minimally invasive diagnosis and treatment. In endometrial cancer cells, expression levels of miRNAs including miR-185, miR-210 and miR-423 are upregulated and those of miR-let7e, miR-30c and miR-221 are downregulated compared to normal tissues, and these miRNAs are involved in carcinogenesis, invasion and metastasis. miRNAs with expression changes such as miR-181b, miR-324-3p and miR-518b may be used as prognostic biomarkers and transfection of miR-152 may inhibit cancer growth. However, most current studies of miRNAs are at a basic level and further work is needed to establish clinical applications targeting miRNAs.

Downloads

Published

2015-02-02

How to Cite

Yanokura, M., Banno, K., Iida, M., Irie, H., Umene, K., Masuda, K., … Aoki, D. (2015). MicroRNAS in endometrial cancer: recent advances and potential clinical applications. EXCLI Journal, 14, 190–198. https://doi.org/10.17179/excli2014-590

Issue

Vol. 14 (2015)

Section

Review articles

License

Authors who publish in this journal agree to the following terms:

  • The authors keep the copyright and grant the journal the right of first publication under the terms of the Creative Commons Attribution license, CC BY 4.0. This licencse permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.
  • The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
  • Because the advice and information in this journal are believed to be true and accurate at the time of publication, neither the authors, the editors, nor the publisher accept any legal responsibility for any errors or omissions presented in the publication. The publisher makes no guarantee, express or implied, with respect to the material contained herein.
  • The authors can enter into additional contracts for the non-exclusive distribution of the journal's published version by citing the initial publication in this journal (e.g. publishing in an institutional repository or in a book).